Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia
| Autor: | Mindaugas Stoškus, Jurgita Sejoniene, Tadas Zvirblis, Vilma Valceckiene, Reda Matuzeviciene, Laimonas Griskevicius, Regina Pileckyte |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
Oncology medicine.medical_specialty Chronic lymphocytic leukemia Antineoplastic Agents High dose methylprednisolone 030204 cardiovascular system & hematology Relapsed chronic lymphocytic leukemia Methylprednisolone elderly Article 03 medical and health sciences 0302 clinical medicine rituximab immune system diseases Internal medicine hemic and lymphatic diseases medicine Humans Prospective Studies 030212 general & internal medicine Progression-free survival Adverse effect Aged Aged 80 and over chronic lymphocytic leukemia high-dose methylprednisolone lcsh:R5-920 business.industry General Medicine medicine.disease Leukemia Lymphocytic Chronic B-Cell Toxicity Female Rituximab lcsh:Medicine (General) business medicine.drug |
| Zdroj: | Medicina Volume 55 Issue 11 Medicina; Volume 55; Issue 11; Pages: 719 Medicina, Basel : MDPI, 2019, vol. 55, no. 11, art. no. 719, p. [1-10] Medicina, Kaunas; Basel : LSMU, MDPI, 2019, vol. 55, no. 11, art. no. 719, p. [1-10] Medicina, Vol 55, Iss 11, p 719 (2019) |
| ISSN: | 1010-660X 1648-9144 |
| DOI: | 10.3390/medicina55110719 |
| Popis: | Background and Objectives: BTK and BCL2 inhibitors have changed the treatment paradigms of high-risk and elderly patients with chronic lymphocytic leukemia (CLL), but their long-term efficacy and toxicity are still unknown and the costs are considerable. Our previous data showed that Rituximab (Rtx) and high-dose methylprednisolone (HDMP) can be an effective and safe treatment option for relapsed high-risk CLL patients. Materials and Methods: We explored the efficacy and safety of a higher Rtx dose in combination with a shorter (3-day) schedule of HDMP in relapsed elderly or unfit CLL patients. Results: Twenty-five patients were included in the phase-two, single-arm trial. The median progression free survival (PFS) was 11 months (range 10&ndash 12). Median OS was 68 (range 47&ndash 89) months. Adverse events (AE) were mainly grade I&ndash II° (77%) and no deaths occurred during the treatment period. Conclusions: 3-day HDMP and Rtx was associated with clinically meaningful improvement in most patients. The median PFS in 3-day and 5-day HDMP studies was similar and the toxicity of the 3-day HDMP schedule proved to be lower. The HDMP and Rtx combination can still be applied in some relapsed high-risk and elderly or unfit CLL patients if new targeted therapies are contraindicated or unavailable. (ClinicalTrials.gov identifier: NCT01576588). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|